Default company panoramic image

OcuSciences, Inc

Rapid, non-invasive, quantitative diagnostic for eye diseases such as diabetic retinopathy or AMD which guides therapy for primary eye care.

  • Stage $500K in TTM Revenue
  • Industry Medical Devices and Equipment
  • Location Ann Arbor Charter Township, MI, USA
  • Currency USD
  • Founded August 2006
  • Employees 5
  • Website

Company Summary

OcuSciences, Inc. is a revenue-stage, medical diagnostic device company commercializing a rapid, non-invasive test for early detection of retinal disease. OcuSciences has developed a proprietary, ocular imaging technique, Retinal Metabolic Analysis(TM), as biomarker for measuring the damage to retinal tissue due to diabetes, macular degeneration, and glaucoma. Primary eye care uses the camera to detect disease and guide therapy.


  • Default avatar
    Kurt RIegger
    President & COO

    Riegger is serial entrepreneur, founder and CEO/COO of 4 venture backed companies. Riegger has 25 years of executive management experience. Leads business development, strategy and fund raising.

  • Default avatar
    Chris Price
    VP Business Development

    Christopher H. Price, PhD, MBA. Price has 30 yrs experience in life sciences and has led 3 life science venture backed companies, raising more than $100M in capital and bringing 5 products into clinical study. He is also an honorary member of the American Diabetes Association. Leads business partnering, licensing deals and IP portfolio management.

  • Default avatar
    Victor Elner
    Chief Medical Officer

    Dr. Victor Elner, PhD, M.D., Ravitz Foundation Professor of Ophthalmology & Visual Sciences and Professor of Pathology at the University of Michigan Kellogg Eye Center is a co-founder of the company, creator of the method, and manages clinical trial design and contract research programs. Dr Elner is a frequent speaker at conferences on AMD and the pathology of disease

  • Default avatar
    Michelle Cote
    Product Manager

    Michelle Cote, MS BioMed Engr. Cote is a graduate of Univ of Michigan Biomedical Engineering School and recipient of the BME Prize for best new medical device in 2010. Cote manages the OcuMet Beacon product family and contract development resources.

  • Default avatar
    John Moore
    Board advisor

    Moore is the former CEO of 4 advanced technology ophthalmic instrument companies including the first OCT instrument. Moore is on the board of OptoVue and Starr Medical. Previously Moore was VP-Alcon and president of division Zeiss Meditec.


  • Default avatar
    Tim Damschroeder, Bodman
    Default avatar
    Jeff Dolowy, Plante Moran

Previous Investors

  • Default avatar